Anzeige
Mehr »
Login
Sonntag, 01.08.2021 Börsentäglich über 12.000 News von 667 internationalen Medien
Patent-Riese schlägt zu! Auffällige Volumina ziehen Käufer an! Aktie geht steil!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853783 ISIN: JP3112000009 Ticker-Symbol: SHJ 
Stuttgart
30.07.21
08:01 Uhr
35,200 Euro
-0,600
-1,68 %
Branche
Chemie
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
AGC INC Chart 1 Jahr
5-Tage-Chart
AGC INC 5-Tage-Chart
RealtimeGeldBriefZeit
35,20036,40031.07.

Aktuelle News zur AGC Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05.07.AGC Biologics to acquire cell and gene therapy manufacturing facility in Longmont, Colorado2
02.07.AGC Biologics expands further in Colorado with purchase of Novartis Gene Therapies plant8
02.07.AGC Biologics to Acquire Novartis Facility in Longmont, CO12
AGC Aktie jetzt für 0€ handeln
01.07.AGC Biologics Enters Agreement to Acquire Facility in Longmont, CO, Eyeing to Significantly Expand Their Cell and Gene Therapy Capabilities and Offerings279Seattle, July 01, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the signing of a purchase agreement...
► Artikel lesen
25.06.AGC Capital, Inc. -- Moody's announces completion of a periodic review of ratings of AGC Inc.2
24.06.Chemomab and AGC Biologics Partner to Manufacture CM-101 for Phase II/III6
23.06.Chemomab and AGC Biologics expand CM-101 manufacturing partnership2
23.06.Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III269AGC Biologics to manufacture CM-101 for Phase II/III trials at their Copenhagen facilityTEL AVIV, Israel and SEATTLE, Wash., June 23, 2021 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd. (NASDAQ: CMMB)...
► Artikel lesen
10.06.AGC adds another major Covid-19 vaccine maker to the client list with BioNTech pact for plasmid DNA36
07.06.AGC Biologics Inks Supply Deal for COVID-19 Vaccine3
07.06.AGC Biologics' Heidelberg Facility to Further Supply Plasmid DNA for COVID-19 Vaccine322Seattle, June 07, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced its partnership with BioNTech SE...
► Artikel lesen
02.06.LET EM KNOW AB: Sigrid Therapeutics inks major manufacturing deal with Japan's AGC for SiPore153
19.05.AGC Inc. Receives Best Acquisition Award for Adding the Former MolMed into AGC Biologics324Seattle, May 19, 2021to the Cell and Gene Therapy Center of Excellence in Milan. The site was the first GMP facility approved in Europe for ex-vivo gene therapy manufacturing and has industry-unique...
► Artikel lesen
07.05.AGC Biologics and Oculis Enter Manufacturing Deal1
06.05.Oculis Selects AGC Biologics' Heidelberg Facility to Manufacture OCS-02432Seattle, May 06, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced its partnership with Oculis to manufacture...
► Artikel lesen
30.04.Horizon Therapeutics plc Selects AGC Biologics to Further Supply KRYSTEXXA (pegloticase injection) at AGC's Copenhagen Facility515Seattle, April 30, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the expansion of their partnership...
► Artikel lesen
28.04.S&P Global Ratings revised outlook on AGC to stable and affirmed at "A-" (Local Currency LT) credit rating1
28.04.S&P Global Ratings revised outlook on AGC to stable and affirmed at "A-" (Foreign Currency LT) credit rating1
27.04.S&P: Japan-Based AGC Inc. Outlook Revised To Stable From Negative On Strong Earnings; 'A-/A-2' Ratings Affirmed1
21.04.AGC Biologics Expands Partnership with Rocket Pharmaceuticals11
Seite:  Weiter >>
59 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1